Delaware House Bill 302
Session 152
An Act To Amend Title 18 Of The Delaware Code Relating To Prostate Cancer Screening.
Introduced
Introduced in Senate on May 7, 2024
Sponsors
16 Sponsors
Stephanie T. Bolden
Peter C. Schwartzkopf
Russell Huxtable
David L. Wilson
Paul S. Baumbach
William Bush
S. Elizabeth Lockman
Kendra Johnson
Sean M. Lynn
Eric Morrison
Stell Parker Selby
Brian Pettyjohn
Madinah Wilson-Anton
Franklin D. Cooke
Edward S. Osienski
Kerri Evelyn Harris
First Action
Apr 11, 2024
Latest Action
May 7, 2024
Origin Chamber
House
Type
Bill
Bill Number
302
State
Delaware
Session
152
Brian Pettyjohn
grade
Primary
David L. Wilson
grade
Primary
Edward S. Osienski
grade
Primary
Eric Morrison
grade
Primary
Franklin D. Cooke
grade
Primary
Kendra Johnson
grade
Primary
Kerri Evelyn Harris
grade
Primary
Madinah Wilson-Anton
grade
Primary
Paul S. Baumbach
grade
Primary
Primary
Russell Huxtable
grade
Primary
S. Elizabeth Lockman
grade
Primary
Sean M. Lynn
grade
Primary
Stell Parker Selby
grade
Primary
Stephanie T. Bolden
grade
Primary
William Bush
grade
Primary
checkPassed on May 7, 2024
Motion Text
SM
House Roll Call Votes
Other
Cyndie Romer
Yes
Other
Other
DeShanna U Neal
Yes
Jeff Hilovsky
Yes
Other
Other
Kerri Evelyn Harris
Yes
Other
Other
Other
Other
Other
Other
Sophie Phillips
Yes
Stell Parker Selby
Yes
Stephanie T. Bolden
Yes
Other
Valerie Jones Giltner
Other
Yes
Summary
According to the American Cancer Society, prostate cancer is the second-leading cause of death from cancer in men. It is estimated that about 1 in 41 men will die of prostate cancer. According to ZERO Prostate Cancer, Black men face serious health care disparities regarding prostate cancer. 1 in 6 Black men will develop prostate cancer in their lifetime compared to 1 in 8 men overall. Black men are also 1.7 times more likely to be diagnosed with, and 2.1 times more likely to die from, prostate cancer than white men.
HB 302 requires all group, blanket, and individual health insurance policies to cover prostate screening for men at risk of prostate cancer. This Substitute bill broadens the definition of “prostate screening” to include any medically necessary and clinically appropriate method for the detection and diagnosis of prostate cancer, including a digital rectal exam and prostate specific antigen test, and associated laboratory work. This Substitute bill also clarifies the ages at which prostate screenings must be covered, consistent with the American Cancer Society guidelines, as follows: (1) Age 50 for men at average risk of developing prostate cancer; (2) Age 45 for men at high risk of developing prostate cancer, including African American men and men who have a first degree relative diagnosed with prostate cancer; and (3) Age 40 for men at even higher risk for prostate cancer, including men who have more than one first degree relative diagnosed with prostate cancer.
This Substitute bill also extends the effective date to health insurance policies modified after December 31, 2025, and makes technical corrections.
Sort by most recent
05/07/2024
Senate
Assigned to Banking, Business, Insurance & Technology Committee in Senate
05/07/2024
House
Passed By House. Votes: 24 YES 3 NO 8 NOT VOTING 6 ABSENT
04/11/2024
House
was introduced and adopted in lieu of HB 302
Sources
Open States
Record Created
Mar 1, 2024 12:47:44 AM
Record Updated
May 13, 2024 9:23:49 PM